Efekti subhroničnog unosa mineralne vode bogate magnezijum hidrokarbonatom na telesnu težinu i kardiovaskularne varijable kod pacova sa dijabetesom izazvanim streptozotocinom

  • Dragan M Djuric Univerzitet u Beogradu, Institut za medicinsku fiziologiju "Prof. Richard Burian"
  • Filip Milošević Faculty of Medicine, University of Belgrade, Serbia
  • Dušan Todorović Institute of Medical Physiology "Richard Burian", Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Vladimir Živković Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Srbija
  • Ivan Srejović Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Srbija
  • Vladimir Jakovljević Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Srbija
  • Miloš P Stojiljković University of Banja Luka Faculty of Medicine
  • Ranko Škrbić University of Banja Luka Faculty of Medicine
  • Dragana Dragičević - Cvjetković Institute of Physical Medicine and Rehabilitation “Dr Miroslav Zotović“, Banja Luka, The Republic of Srpska, Bosnia & Herzegovina
  • Sonja Vučković Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia & Herzegovina, Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, The Republic of Srpska, Bosnia & Herzegovina
DOI: https://doi.org/10.5937/scriptamed53-41584
Ključne reči: Magnezijum, Diabetes mellitus, Krvni pritisak, Telesna težina, Težina organa

Sažetak


Background/Aim: Optimal intake of magnesium minerals is essential in maintaining the coordinated physiological functions of cells, tissues and organs. The importance of this element is reflected in the fact that it is the fourth most abundant cation in the human body, participating as a cofactor in more than three hundred enzymatic reactions. Its presence is necessary for the proper functioning of a number of vital functions, such as glycaemic control, the work of the heart and the vascular system and it can potentially play a role in the regulation of body weight. Aim of this study was to investigate the effects of subchronic intake of magnesium hydrocarbonate-rich water on changes in body weight, organ weight and cardiovascular variables in rats with streptozotocin-induced diabetes.

Methods: Wistar rats (n = 28) were divided into 4 groups: two control groups, on tap water (TW-C, n = 7) and magnesium hydrocarbonate-rich water (MW-C, n = 7); and two experimental groups with streptozotocin-induced diabetes, on tap water (TW-DM, n = 7) and magnesium hydrocarbonate-rich water (MW-DM, n = 7). The values ​​of body weight, organ weight and cardiovascular parameters were compared after 6 weeks between control groups of rats on subchronic treatment with tap water (TW-C) and magnesium hydrocarbonate-rich water (MW-C) and between groups with streptozotocin-induced diabetes on tap water (TW-DM) and with magnesium hydrocarbonate-rich water (MW-DM).

Results: By comparing the values ​​of cardiovascular parameters between groups, significant (p < 0.05) positive effects of magnesium hydrocarbonate were registered on the values ​​of systolic and pulse blood pressure in diabetic rats fed with magnesium hydrocarbonate-rich water (MW-DM) compared to those fed with tap water (TW-DM). In contrast, no significant effect of magnesium hydrocarbonate on changes in body weight and organ weight was observed.

Conclusion: Based on the results, the beneficial effects of magnesium hydrocarbonate in the regulation of blood pressure can be clearly observed. Potential effects on other cardiovascular variables and body weight and organ weight should be further investigated.

Reference

1.      1.      European Food Safety Authority (EFSA). Scientific opinion on dietary reference values for magnesium. EFSA Journal 2015;13(7):4186. doi: 10.2903/j.efsa.2015.4186.

2.      Saris N, Mervaala E, Karppanen H, Khawaja J, Lewenstam A. Magnesium. Clin Chim Acta 2000;294(1-2):1-26.

3.      Bertinato J, Xiao C, Ratnayake W, Fernandez L, Lavergne C, Wood C, et al. Lower serum magnesium concentration is associated with diabetes, insulin resistance and obesity in South Asian and white Canadian women but not men. Food Nutr Res 2015 May 5;59:25974. doi: 10.3402/fnr.v59.25974.

4.      Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients 2015;7(9):8199-226.

5.      Noronha L, Matuschak G. Magnesium in critical illness: metabolism, assessment and treatment. Intensive Care Med 2002;28(6):667-79.

6.      Cruz K, de Oliveira A, Pinto D, Morais J, da Silva Lima F, Colli C, et al. Influence of magnesium on insulin resistance in obese women. Biol Trace Elem Res 2014 Sep;160(3):305-10.

7.      de Baaij J, Hoenderop J, Bindels R. Magnesium in man: Implications for health and disease. Physiol Rev 2015;95(1):1-46.

8.      Dong J, Xun P, He K, Qin L. Magnesium intake and risk of type 2 diabetes. Diabetes Care 2011;34(9):2116-22.

9.      Bertinato J, Wang K, Hayward S. Serum magnesium concentrations in the Canadian population and associations with diabetes, glycemic regulation and insulin resistance. Nutrients 2017;9(3):296. doi: 10.3390/nu9030296.

10.   Zhao B, Zeng L, Zhao J, Wu Q, Dong Y, Zou F, et al. Association of magnesium intake with type 2 diabetes and total stroke: An updated systematic review and meta-analysis. BMJ Open 2020;10(3):e032240. doi: 10.1136/bmjopen-2019-032240.

11.   Barbagallo M, Dominguez L. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007 Feb 1;458(1):40-7.

12.   Esmeralda C, David P, Maldonado I, Ibrahim S, David A, Escorza M, et al. Deranged fractional excretion of magnesium and serum magnesium levels in relation to retrograde glycaemic regulation in patients with type 2 diabetes mellitus. Curr Diabetes Rev 2020;17(1):91-100.

13.   Hruby A, McKeown N. Magnesium deficiency. Nutrition Today 2016;51(3):121-8.

14.   Kieboom B, Ligthart S, Dehghan A, Kurstjens S, de Baaij J, Franco O, et al. Serum magnesium and the risk of prediabetes: a population-based cohort study. Diabetologia 2017;60(5):843-53.

15.   Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care 2003;26(4):1147-52.

16.   Lalovic D, Jakovljevic V, Radoman K, Bradic J, Jeremic N, Vranic A, et al. The impact of low mineral content water on cardiac function in diabetic rats: focus on oxidative stress. Mol Cell Biochem 2020;472(1-2):135-44.

17.   Paravicini T, Yogi A, Mazur A, Touyz R. Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited hypomagnesemia. Hypertension 2009;53(2):423-9.

18.   Satake K, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Yue H, Ueda T. Effects of magnesium on prostacyclin synthesis and intracellular free calcium concentration in vascular cells. Magnes Res 2004;17(1):20-7.

19.   Landau R, Scott J, Smiley R. Magnesium-induced vasodilation in the dorsal hand vein. BJOG 2004;111(5):446-51.

20.   Soltani N, Keshavarz M, Sohanaki H, Zahedi Asl S, Reza Dehpour A. Relaxatory effect of magnesium on mesenteric vascular beds differs from normal and streptozotocin induced diabetic rats. Eur J Pharmacol 2005;508(1-3):177-81.

21.   Touyz RM, Yao G. Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats. J Hypertens 2003;21(2):337-44.

22.   Blache D, Devaux S, Joubert O, Loreau N, Schneider M, Durand P, et al. Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Biol Med 2006 Jul 15;41(2):277-84.

23.   Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992;110(2):169-73.

24.   Nadler JL, Rude RK. Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 1995;24(3):623-41. 

25.   DiNicolantonio J, Liu J, O’Keefe J. Magnesium for the prevention and treatment of cardiovascular disease. Open Heart 2018;5(2):e000775. doi: 10.1136/openhrt-2018-000775.

26.   Del Gobbo L, Song Y, Poirier P, Dewailly E, Elin R, Egeland G. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol 2012;11(1):23. doi: 10.1186/1475-2840-11-23.

27.   Efstratiadis G, Sarigianni M, Gougourelas I. Hypomagnesemia and cardiovascular system. Hippokratia 2006;10(4):147-52.

28.   Janeira LF. Torsades de pointes and long QT syndromes. Am Fam Physician 1995;52(5):1447-53.

29.   Isayama S, Ushijima K, Sakanashi Y, Yano T, Terasaki H. Sudden ventricular tachyarrhythmia immediately following hepatectomy in a patient with hypomagnesemia. Masui 1998;47(4):470-4.

30.   Onagawa T, Ohkuchi A, Ohki R, Izumi A, Matsubara S, Sato I et al. Woman with postpartum ventricular tachycardia and hypomagnesemia. J Obstet Gynaecol Res 2003 Apr;29(2):92-5.

31.   Kaye A, Volpi-Abadie J, Bensler J, Kaye A, Diaz J. QT interval abnormalities: risk factors and perioperative management in long QT syndromes and torsades de pointes. J Anesth 2013;27(4):575-87.

32.   Ganga H, Noyes A, White C, Kluger J. Magnesium adjunctive therapy in atrial arrhythmias. Pacing Clin Electrophysiol 2013 Oct;36(10):1308-18.

33.   Iseri L. Role of magnesium in cardiac tachyarrhythmias. Am J Cardiol 1990 Jun 19;65(23):47K-50K.

34.   Hicks K, Seifen E, Stimers J, Kennedy R. Effects of streptozotocin-induced diabetes on heart rate, blood pressure and cardiac autonomic nervous control. J Auton Nerv Syst 1998 Mar 3;69(1):21-30.

35.   Laurant P, Hayoz D, Brunner HR, Berthelot A. Effect of magnesium deficiency on blood pressure and mechanical properties of rat carotid artery. Hypertension 1999;33(5):1105-10.

36.   Laurant P, Kantelip JP, Berthelot A. Dietary magnesium supplementation modifies blood pressure and cardiovascular function in mineralocorticoid-salt hypertensive rats but not in normotensive rats. J Nutr 1995;125(4):830-41.

37.   Jelicks LA, Gupta RK. Intracellular free magnesium and high energy phosphates in the perfused normotensive and spontaneously hypertensive rat heart. A 31P NMR study. Am J Hypertens 1991;4(2 pt 1):131–6.

38.   Ryan M, Brady H. The role of magnesium in the prevention and control of hypertension. Ann Clin Res 1984;16(43):81–8.

39.   Shibutani Y, Sakamoto K, Katsuno S, Yoshimoto S, Matsuura T. Serum and erythrocyte magnesium levels in junior high school students: relation to blood pressure and a family history of hypertension. Magnesium 1988;7(4):188–94.

40.   Rylander R, Arnaud M. Mineral water intake reduces blood pressure among subjects with low urinary magnesium and calcium levels. BMC Public Health 2004;4:56. doi: 10.1186/1471-2458-4-56.

41.   Zhang X, Li Y, Del Gobbo L, Rosanoff A, Wang J, Zhang W, et al. Effects of magnesium supplementation on blood pressure. Hypertension 2016;68(2):324-33.

42.   Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr 2012 Apr;66(4):411-8.

43.   Surawicz B. Is hypomagnesemia or magnesium deficiency arrhythmogenic? J Am Coll Cardiol 1989;14(4):1093-6.

44.   Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013;127(1):33-8.

45.   DeCarli C, Sprouse G, LaRosa JC. Serum magnesium levels in symptomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol 1986;57(11):956-9.

46.   Lewis RV, Tregaskis B, McLay J, Service E, McDevitt DG. Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation. Eur J Clin Pharmacol 1990;38(2):107-10.

47.   Djuric D, Gatarić N, Todorović D, Stanković S, Dragičević-Cvjetković D, Stojiljković M, et al. The effects of subchronic intake of magnesium hydrocarbonate-rich mineral water on cardiometabolic markers and electrolytes in rats with streptozotocin-induced diabetes. Scr Med 2022;53(3):197-204.

Objavljeno
2022/12/28
Broj časopisa
Vol. 53 Br. 4 (2022): Q4/December
Rubrika
Originalni naučni članak
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).